Annual Variant-Targeted Vaccination to Prevent Severe COVID-19 in Cohorts With Vaccine-Derived and Hybrid Immunity
In cohorts with vaccine-derived and hybrid immunity, modest but significant gains in protection against hospitalization and severe COVID-19 illness were conferred by the annual variant-targeted booster dose but not sustained beyond 6 months.
Authors
- Phyllis C. Tien
- Charles Austin (ORCID: https://orcid.org/0000-0002-5253-0623)
- Katherine J. Hoggatt (ORCID: https://orcid.org/0000-0002-9431-5438)
- W. John Boscardin (ORCID: https://orcid.org/0000-0003-3121-9526)
- Hye Sun Kim
- Peter C. Austin (ORCID: https://orcid.org/0000-0003-3337-233X)
- Amy L. Byers
- John Daniel Kelly (ORCID: https://orcid.org/0000-0002-7616-0321)
- Dawn M. Bravata (ORCID: https://orcid.org/0000-0002-3048-2536)
- Emily N. Lum
- Nathan C. Lo (ORCID: https://orcid.org/0000-0002-5407-2005)
- Salomeh Keyhani (ORCID: https://orcid.org/0000-0001-9124-9618)
- Samuel Leonard
Institutions
- Regenstrief Institute (US)
- University of California, San Francisco (US)
- Veterans Health Administration (US)
- Indianapolis Zoo (US)
- San Francisco Foundation (US)
- Richard L. Roudebush VA Medical Center (US)
- Stanford Medicine (US)
- San Francisco VA Health Care System (US)
- Institute for Clinical Evaluative Sciences (CA)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- Stanford University (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1093/cid/ciaf124
- Citations
- 5
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 6.98
Funders
- U.S. Department of Veterans Affairs
- Clinical Science Research and Development
- National Institute of Allergy and Infectious Diseases